Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$2.41
-$0.18(-4.10%)
At close: 4:00 PM EDT
$2.41
-$0.18(-4.10%)
Day’s Range― - ―
52-Week Range$1.37 - $45.90
Previous Close$4.12
Volume37.98K
Average Volume (3M)145.97K
Market Cap
$3.26M
Enterprise Value-$0.28
Total Cash (Recent Filing)$9.80M
Total Debt (Recent Filing)$4.21M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Nov 05, 2026EPS Estimate
-3.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-211.18
Shares Outstanding1,810,215
10 Day Avg. Volume337,020
30 Day Avg. Volume145,969
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.00Price Target Upside771.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-19.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Encouraging AML Clinical EfficacyThe reported responses in high-risk TP53-mutated AML suggest mipletamig may address a population with substantial unmet need. If confirmed in the ongoing RAINIER study, this clinical differentiation could improve partnering prospects and support a durable development pathway.
Expandable Solid-tumor PlatformA reusable Nectin-4 x PD-L1 backbone could support several therapeutic formats rather than a single asset, broadening the company’s pipeline options. The patent filing and platform approach may strengthen intellectual property, partnering potential, and long-term development leverage.
Non-dilutive Development FundingThe grant provides targeted funding for APVO451’s IND-enabling work while allowing Aptevo to retain project-related intellectual property. This reduces the amount of equity capital needed for the program and supports continued progress toward candidate selection and clinical preparation.
Bears Say
No Commercial RevenueThe absence of reported revenue means Aptevo currently lacks commercial activity to fund its operating base, leaving value creation dependent on clinical progress and partnerships. Persistent large losses also make the path to self-sustaining profitability uncertain over the medium term.
Persistent Cash BurnSubstantial recurring cash outflows indicate that research and development spending is not yet supported by operating cash generation. Continued burn increases dependence on external funding, constrains strategic flexibility, and raises the risk that future programs require additional capital before reaching milestones.
Financing And Dilution RiskThe financing improves near-term liquidity but creates potential dilution through newly issued shares and warrants. Because the company is loss-making and cash-burning, repeated reliance on equity-linked funding could reduce existing ownership and increase the capital required to advance the pipeline.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $1.37 and its highest was $45.90 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $3.26M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 49 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Aug 14, 2026. The company reported -$5.31 earnings per share for the quarter, beating the consensus estimate of -$6.015 by $0.705.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -3.72.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,810,215 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$5.31 in its last earnings report, beating expectations of -$6.015. Following the earnings report the stock price went down -13.529%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(771.37% Upside)
Technical Analysis
Ownership Overview
0.37% Insiders
1.23% Mutual Funds
<0.01% Other Institutional Investors
97.69% Public Companies and
Individual Investors